Every story in this section, newest first — page 252 of 373.
The Trump administration formally defended the Pentagon’s blacklisting of Anthropic in a Tuesday court filing, asserting that the designation of the artificial intelligence firm as a national security threat was both justified and lawful.
Biotech royalty aggregator XOMA Royalty 9NASDAQ:XOMA) reported a sharp financial turnaround for its 2025 fiscal year, swinging to a robust profit on the back of surging revenues and executing multiple shareholder-value initiatives.
Boyd Group Services (NYSE:BGSI) reported its financial results for the full year ended December 31, 2025, highlighting a year of significant structural growth and market consolidation.
UCLOUDLINK GROUP (NASDAQ:UCL) announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025, highlighting a successful transition toward a high-margin, diversified service model.
Hello Group (NASDAQ:MOMO) reported unaudited financial results for the fourth quarter and full year ended December 31, 2025, revealing a strategic pivot toward global markets.
AerCap (NYSE:AER) today announced a major commitment to the future of single-aisle aviation, confirming an order for 100 Airbus A320neo Family aircraft.
A high-stakes rift has emerged between the world’s most powerful AI alliance as Microsoft (NASDAQ:MSFT) considers litigation against OpenAI and Amazon (NASDAQ:AMZN).
Defence Minister Richard Marles confirms RAAF E-7A Wedgetail surveillance data is being shared with a US-run command centre in Qatar.
BHP Group (ASX:BHP) announced the appointment of Brandon Craig as its next CEO, effective July 1.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) released new 24-week results from the highest dose cohort of its Phase 1b/2a RESOLVE trial, evaluating EP-104GI for the treatment of eosinophilic esophagitis (EoE).
Monte Rosa Therapeutics (NASDAQ:GLUE) reported a net loss of $46.1 million for the fourth quarter ended December 31, 2025.
Nebius Group (NASDAQ:NBIS) announced a strategic collaboration with Nvidia (NASDAQ:NVDA) to accelerate the development of physical artificial intelligence, providing a unified platform for the entire robotics lifecycle.
Llulemon athletica (NASDAQ:LULU) announced its financial results for the fourth quarter and fiscal year ended February 1, 2026, revealing a tale of two markets.
Titan America (NYSE:TTAM) announced today its financial results for the fourth quarter and full year ended December 31, 2025, highlighting a period of sustained growth and operational efficiency.
Docusign (NASDAQ:DOCU) reported robust financial results for its fourth quarter and fiscal year ended January 31, 2026, demonstrating its resilience as it evolves beyond simple e-signatures into a comprehensive agreement management powerhouse.
High Tide (NASDAQ:HITI) reported its financial results for the first fiscal quarter ended January 31, 2026, marking its strongest start to a fiscal year to date.
Oklo (NYSE:OKLO) shares surged as much as 7% Tuesday before paring gains after the nuclear technology developer announced a safety design agreement with the U.S. Department of Energy to support the design, construction and operation of its first Aurora reactor at Idaho National Laboratory.
Coda Octopus Group (NASDAQ:CODA) reported robust financial results for its fiscal first quarter ended January 31, 2026, highlighting a period of accelerated growth for its high-definition underwater imaging platforms.
Bicycle Therapeutics (NASDAQ:BCYC), a biotechnology firm pioneering "Bicycle" peptide technology, reported its fourth-quarter and full-year 2025 financial results on March 17, 2026.
General Mills (NYSE:GIS) announced today that it has entered into a definitive agreement to divest its operations in Brazil to Grupo 3corações, a leading Brazilian food and beverage company.
Gyre Therapeutics (NASDAQ:GYRE) reached a critical regulatory milestone as the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) granted Priority Review status to the New Drug Application (NDA) for Hydronidone (F351).
Kalaris (NASDAQ:KLRS) reported its fourth-quarter and full-year 2025 financial results today, delivering a clinical update that positions its lead candidate as a potential disruptor in the $13 billion anti-VEGF market.
Expion360 (NASDAQ:XPON) on Tuesday reported full-year 2025 net sales of $9.7 million for the period ended December 31, 2025, an increase of 72% from the prior year, reflecting continued expansion in lithium battery solutions for recreational vehicles, marine and industrial applications.
Comstock Holding Companies (NASDAQ:CHCI) reported robust financial results for the fourth quarter and full year ended December 31, 2025, extending its streak of year-over-year revenue growth to 28 consecutive quarters.
